Heterocyclic KRAS Degrader Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pancreatic cancer and lung cancer, particularly those targeting G12V mutant KRAS, lack effective therapeutic agents that can induce degradation of the G12V mutant KRAS protein, leading to limited therapeutic efficacy.
Innovation Solution
A heterocyclic compound, specifically a bifunctional compound with a substituent on the 8-position of quinazoline or quinoline, is designed to bind with an E3 ligase via a linker, effectively inducing degradation of the G12V mutant KRAS protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents (FOLFIRINOX, Erlotinib) are used to treat pancreatic cancer and lung cancer, then therapeutic effects are achieved to some extent, but the therapeutic efficacy is limited and toxicity is strong
Solution Approach 1:
The invention changes the mechanism of action parameter from inhibition to degradation induction. By designing bifunctional compounds that recruit E3 ligases to degrade G12V mutant KRAS protein, the therapy achieves more reliable therapeutic efficacy while potentially reducing toxicity associated with conventional chemotherapy agents
Solution Approach 2:
The invention uses composite molecular structure combining a G12V mutant KRAS-binding heterocyclic compound with an E3 ligase-recruiting moiety connected by a linker. This composite bifunctional compound enables simultaneous binding to the target protein and recruitment of degradation machinery, achieving enhanced therapeutic effect
2Reliability
If G12V mutant KRAS inhibitors are developed to improve therapeutic effect, then degradation-inducing action is needed, but no effective degradation inducer has been found yet
Solution Approach 1:
The invention introduces an intermediary mechanism by recruiting E3 ligases as mediators to induce degradation of G12V mutant KRAS protein. The bifunctional compound acts as a bridge between the target protein and the degradation machinery, enabling effective degradation-inducing action that was previously unavailable
Solution Approach 2:
The invention creates a universal platform for degrading G12V mutant KRAS by designing bifunctional compounds that can recruit different E3 ligases. This multi-functional approach provides versatility in achieving degradation induction across different contexts
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound exhibits strong degradation-inducing action on G12V mutant KRAS, offering potential therapeutic benefits for pancreatic cancer and lung cancer, especially G12V mutant KRAS-positive cases.
Implementation Method 1
such a bifunctional compound promotes formation of a composite of the target protein and an E3 ligase in a cell, and degradation of the target protein is induced using the ubiquitin-proteasome system
Data Source
AI summary
A compound as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and/or lung cancer. The compound is a heterocyclic compound represented by formula (I) and has an excellent degradation-inducing action on a G12V mutant KRAS protein and a G12V mutant KRAS inhibition activity. The heterocyclic compound or a salt thereof can be used as a therapeutic agent for pancreatic cancer and/or lung cancer.